Table 2.

Mortality Risk by DHEAS Trajectory Parameter^*

		Both sexes	Men only	Women only
Model	Measure	HR (95% CI)	HR (95% CI)	HR (95% CI)
Baseline† only	Baseline	0.95 (0.86–1.04)	0.93 (0.81–1.07)	1.37 (1.03, 1.83)
				1
				1.41 (0.95–2.09)
Slope‡ only	No steep decline	1	1	1
	Steep decline	1.99 (1.50–2.64)	2.53 (1.74–3.67)	1.51 (0.98–2.33)
Variability§ only	Minimal variability	1	1	1
	Moderate variability	1.36 (1.11–1.67)	1.24 (0.93–1.64)	1.51 (1.13–2.03)
	Extreme variability	2.09 (1.63–2.67)	3.33 (2.37–4.67)	1.38 (0.95–1.98)
Baseline†, slope‡, and variability§	Baseline	0.97 (0.88–1.07)	0.99 (0.86–1.13)	1.33 (0.99–1.78)
				1
				1.34 (0.90–2.00)
	No steep decline	1	1	1
	Steep decline	1.75 (1.32–2.33)	2.08 (1.46–2.98)	1.34 (0.86–2.10)
	Minimal variability	1	1	1
	Moderate variability	1.29 (1.05–1.59)	1.13 (0.84–1.52)	1.47 (1.09–1.97)
	Extreme variability	1.89 (1.47–2.43)	2.91 (2.07–4.11)	1.27 (0.87–1.85)

Notes: CI, confidence interval; DHEAS, dehydroepiandrosterone sulfate; HR, hazard ratio.

^*All models adjusted for age, race, cardiovascular disease, pulmonary disease, diabetes, cancer, and depression. Models of combined sexes were also adjusted for sex.

^†Baseline DHEAS level reported per standard deviation for both sexes and men only, categorized into three categories (Decile 1–2, Decile 3–8 [reference], and Decile 9–10) for women only.

^‡The cutpoint separating not steep and steep decline is −0.11%/y.

^§The cutpoints separating minimal, moderate, and extreme variability are 0.17% and 0.30%.